Remicade Biosimilars Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

1. Remicade Biosimilars Market - Size, Share, Remicade Biosimilars Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026 Outlook, and Opportunity Analysis, 2018-2026 Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an existing licensed reference therapeutic drug. Biological products are the fastest growing class of therapeutic products, as they offer additional treatment options and help in lowering healthcare costs. Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only when the patent for the original innovator drug expires. These products are highly sensitive to smallest changes in manufacturing procedure, as these drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of Remicade due to cost-effective prices. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1769 Regional Insights On the basis of region, the global Remicade biosimilar market is segmented into North America, Latin America, Europe, Asia Pacifc, Middle East, and Africa. Europe holds a dominant position in the global Remicade biosimilar market and is expected to retain its dominance over the forecast period, owing to the presence of top market players in the region, rapid entry of biosimilars in the European market as well as high adoption rate due low price of the biosimilars. For instance, in 2018, Sandoz, a Novartis division received European Commission (EC) approval for Zessly (infliximab) a remicade biosimilar for use in Europe. The successive research and speedy approvals by the U.S. regulatory authorities for market entry of biosimilars in North America is expected to drive growth of the market over the forecast period. For instance, in December 2017, Pfzer, Inc. received the U.S. FDA approval for second biosimilar, Ifxi to Janssen’ss blockbuster drug Remicade to treat rheumatoid arthritis.

2. Furthermore, Asia Pacifc is expected to witness signifcant growth in the market over the forecast period, owing to developments in healthcare infrastructure and U.S. FDA approval of Remicade (infliximab) biosimilars by regional players to market the products internationally. For instance, in April 2016, Celltrion- a South Korea-based manufacturing company received the U.S. FDA approval for intravenously administered version of the rheumatoid arthritis drug sold under the name Infllectra. Moreover, major investments by regional players for research and development of biosimilar production is expected to drive growth of the market in Asia. For instance, in October 2016, Cipla, Inc. invested US$ 8 million to set up a manufacturing plant for biosimilars in South Africa. Report includes chapters which deeply display the following deliverable about industry : • Remicade Biosimilars Market Research Objective and Assumption • Remicade Biosimilars Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Remicade Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Remicade Biosimilars Market, By Regions • Remicade Biosimilars Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Remicade Biosimilars Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Remicade Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Remicade Biosimilars Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others. Inquire Here Before Purchase:

3. https://www.coherentmarketinsights.com/insight/talk-to-analyst/1769 Market Taxonomy On the basis of disease indication, the global Remicade biosimilars market is segmented into: Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Crohn’ss Disease Psoriatic Arthritis Plaque Psoriasis • • • • • • On the basis of geography, the global Remicade biosimilars market is segmented into: North America Latin America Europe Asia Pacifc Middle East Africa • • • • • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com